A phase 2 trial of QL1706 and fruquintinib in colorectal cancer, run by Tao Zhang, not yet recruiting.
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. is a phase 2, randomised interventional study registered as NCT07353268 by Tao Zhang, with a registry enrolment figure of 76 participants, started 2026-01-21 and due to reach its primary completion in 2027-08-31. Interventions recorded: QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART); Standard Third-Line Therapy. Conditions listed: Colorectal Cancer. Primary outcome: Progression Free Survival(PFS). Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic colorectal cancer with unresectable liver metastasis(es) measuring ≥5 cm in the longest diameter". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/